Managing CLL Treatment in the Frontline Setting

Pirtobrutinib shows significant improvements in patient-reported outcomes for relapsed CLL/SLL, outperforming standard therapies in a recent trial.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

DZD8586 achieved a high response rate in patients with relapsed/refractory CLL/SLL.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects.

During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.